Clinical Trial Update: Campath, Rituximab, and Myfortic With Short-Course Calcineurin Inhibitor Therapy in Renal Transplanation [NA]

View source ↗

Summary

A renal transplant trial evaluating Campath (alemtuzumab), rituximab, and Myfortic with short-course calcineurin inhibitor therapy was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rejection
• Renal Transplantation

Drugs mentioned

• CAMPATH (ALEMTUZUMAB)
• MYFORTIC (MYCOPHENOLIC ACID)
• Rituximab (rituximab)

Snippet

Sponsor: University of Wisconsin, Madison | Conditions: Acute Rejection, Renal Transplantation | NA | Status: TERMINATED